Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
- Conditions
- Haemophilia A
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT04334057
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 494
- Registration Number
- NCT04315688
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Vyksa, Russian Federation
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT04287179
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes
- Conditions
- Healthy VolunteersDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT04262661
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 789
- Registration Number
- NCT04261933
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Zwenkau, Germany
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
- Conditions
- OverweightObesityDiabetes Mellitus, Type 2Healthy Volunteers
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 152
- Registration Number
- NCT04259801
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
- Conditions
- ObesityOverweightDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 375
- Registration Number
- NCT04251156
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
🇧🇷Instituto de Ciências Farmacêuticas de Estudos e Pesquisas, Aparecida de Goiania, Goias, Brazil
🇧🇷CPCLIN - Centro de Pesquisas Clínicas, São Paulo, Sao Paulo, Brazil
A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 111
- Registration Number
- NCT04238962
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT04228354
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: Insulin degludec
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 938
- Registration Number
- NCT04227431
- Locations
- 🇨🇳
NIS-CNPC Central Hospital, Langfang, Hebei, China
🇨🇳NIS-Langfang people's Hospital, Langfang, Hebei, China
🇨🇳NIS-The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China